FDMT: Utang marang Ekuitas 4dmoleculartherapeutics.com

FDMT (4D Molecular Therapeutics) - tandha merek perusahaan

This daily price chart for 4D Molecular Therapeutics (FDMT) on the GURU.Markets platform, where the debt-to-equity ratio stands at 0.10, reflects the business's dependence on the validation of vector performance and the success of macular dystrophy therapy. The company attracts a team of top biologists through stock options and scientific freedom. Currently, the startup is scaling its ophthalmological and cardiological developments by implementing innovative treatment standards.

FDMT: Total Utang marang Modal 4D Molecular Therapeutics Inc 04.07.2022 - 31.10.2026

Rincian analitis perusahaan 4D Molecular Therapeutics

- rega saham lan konsensus proyeksi valuasi:
Rega saham 4D Molecular Therapeutics, Inc.|FDMT - Prakiraan gabungan firma investasi
- informasi kapitalisasi pasar:
Nilai pasar 4D Molecular Therapeutics|FDMT - Nilai Bisnis
- rincian nilai buku perusahaan:
Nilai Buku saben Saham 4D Molecular Therapeutics|FDMT - Kapitalisasi Buku|Rasio Kapitalisasi marang Nilai Buku 4dmoleculartherapeutics.com|FDMT - Total Aset Perusahaan
- statistik kawajiban utang lan likuiditas:
Rasio Utang marang Ekuitas 4D Molecular Therapeutics|FDMT - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal 4D Molecular Therapeutics|FDMT - Utang perusahaan|Utang marang nilai buku 4D Molecular Therapeutics|FDMT - Utang jangka dawa perusahaan|Utang jangka cendhak 4D Molecular Therapeutics|Likuiditas cepet 4dmoleculartherapeutics.com
- informasi bathi lan kelipatan valuasi:
FDMT - Bathi resik
Ringkesan analisis perusahaan:4D Molecular Therapeutics, Inc.
Produk mawa merek 4D Molecular Therapeutics

Defensive portfolio screening requires strict control of debt load to minimize default risks. This indicator is calculated as the sum of all liabilities divided by the company's equity. For 4D Molecular Therapeutics (FDMT), a low level of borrowing is critical, as the company finances its staff of elite biologists primarily through equity issuance. The total debt-to-equity ratio reflects the sustainability of this development model.

Pesaing wigati

TEM (tempus.com) - Total Utang marang Modal|Rasio Utang marang Ekuitas QGEN (Qiagen NV)|Utang marang Ekuitas Ionis Pharma (IONS)|Repligen Inc. - Rasio Utang marang Ekuitas|Total Utang marang Modal RNA (Avidity Biosciences)|Total Utang marang Modal crisprtx.com CRSP|GeneDx (WGS) - Rasio Utang marang Ekuitas|RARE - Total Utang marang Modal|Rasio Utang marang Ekuitas Beam Therapeutics Corp|Rasio Total Utang marang Ekuitas Sarepta Corp|TWST - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas TXG|Rasio Total Utang marang Ekuitas NTLA (Intellia Therapeutics, Inc.)|Utang marang Ekuitas STOK (Stoke Therapeutics Inc)|BLFS: Utang marang Modal|Wave Pharma - Utang marang Ekuitas|MAZE - Utang marang Ekuitas|SION - Total Utang marang Modal|Utang marang Modal PRME|Taysha Gene Therapies Inc (TSHA) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas QURE|Rasio Total Utang marang Ekuitas MeiraGTx Corp (MGTX)|Total Utang marang Modal RGNX|Utang marang Ekuitas SLDB (solidbio.com)|Utang marang Ekuitas Ocugen OCGN|Total Utang marang Modal Pacific Biosciences of California, Inc. PACB|Benitec - Total Utang marang Modal|DSGN: Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi Rocket Pharmaceuticals RCKT|Rasio Total Utang marang Ekuitas Lexeo Therapeutics, Inc.|KRRO - Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas Editas Medicine Inc (EDIT)|Utang Agregat marang Modal Silence Therapeutics Inc.|Total Utang marang Modal proqr.com (PRQR)|Rasio Kabeh Utang marang Dana Pribadi Codexis|Total Utang marang Modal sangamo.com SGMO|NAUT (Nautilus Biotechnology Inc) - Utang marang Modal|MGX: Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi Precision BioSciences, Inc. DTIL|Generation Bio (GBIO) - Total Utang marang Modal|BOLD (Boundless Bio, Inc.) - Total Utang marang Modal|Utang marang Ekuitas XCUR|IMNN - Utang Agregat marang Ekuitas|Total Utang marang Modal phiopharma.com (PHIO)|MBIO: Utang marang Modal|RNAZ - Rasio Total Utang marang Ekuitas|Bionano - Total Utang marang Modal|adnas.com (APDN) - Rasio Total Utang marang Ekuitas|BLUE - Utang Agregat marang Modal|ImmunoPrecise Antibodies Ltd. (IPA) - Total Utang marang Modal|OMGA: Koefisien Total Utang marang Modal|Total Utang marang Modal Singular Genomics Corp|Rasio Total Utang marang Ekuitas RGLS (Regulus Therapeutics)|Utang marang Ekuitas SYRS (syros.com)|Koefisien Total Utang marang Modal TBIO|Total Utang marang Modal TRACON Pharmaceuticals Inc. TCON|Utang Agregat marang Ekuitas Unity Bio